MATINAS BIOPHARMA HOLDINGS, INC. Operating Expenses
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Operating Expenses of $3.45 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2017-11-14
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for the quarter ending 2017-09-30 was $3.45M, a 88.17% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for the quarter ending 2017-06-30 was $4.02M, a 148.19% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for the quarter ending 2017-03-31 was $4.50M, a 101.22% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for the quarter ending 2016-12-31 was $2.56M, a 7.84% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for fiscal 2016 was $8.26M, a 18.29% decline from fiscal 2015.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for fiscal 2015 was $10.11M, a 3.43% decline from fiscal 2014.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for fiscal 2014 was $10.46M, a 181.89% increase from fiscal 2013.
- MATINAS BIOPHARMA HOLDINGS, INC. operating expenses for fiscal 2013 was $3.71M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 32 month |
|---|---|---|---|---|---|---|
| 2017-09-30 | $3.45M 10-Q · filed 2017-11-14 | $7.47M derived: sum of 2 quarters · filed 2017-11-14 | $11.98M 10-Q · filed 2017-11-14 | $14.54M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-06-30 | $4.02M 10-Q · filed 2017-08-08 | $8.52M 10-Q · filed 2017-08-08 | $11.09M derived: sum of 3 quarters · filed 2017-08-08 | $12.92M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-03-31 | $4.50M 10-Q · filed 2017-05-15 | $7.07M derived: sum of 2 quarters · filed 2017-05-15 | $8.90M derived: sum of 3 quarters · filed 2017-11-14 | $10.52M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $4.40M derived: sum of 2 quarters · filed 2017-11-14 | $6.02M derived: sum of 3 quarters · filed 2017-11-14 | $8.26M 10-K · filed 2017-03-31 | ||
| 2016-09-30 | $1.84M 10-Q · filed 2017-11-14 | $3.46M derived: sum of 2 quarters · filed 2017-11-14 | $5.69M 10-Q · filed 2017-11-14 | $8.48M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | $1.62M 10-Q · filed 2017-08-08 | $3.86M 10-Q · filed 2017-08-08 | $6.64M derived: sum of 3 quarters · filed 2017-08-08 | $8.86M derived: sum of 4 quarters · filed 2017-08-08 | ||
| 2016-03-31 | $2.24M 10-Q · filed 2017-05-15 | $5.02M derived: sum of 2 quarters · filed 2017-05-15 | $7.24M derived: sum of 3 quarters · filed 2017-05-15 | $9.72M derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $5.00M derived: sum of 2 quarters · filed 2017-03-31 | $7.48M derived: sum of 3 quarters · filed 2017-03-31 | $10.11M 10-K · filed 2017-03-31 | ||
| 2015-09-30 | $2.22M 10-Q · filed 2016-11-14 | $4.70M derived: sum of 2 quarters · filed 2016-11-14 | $7.32M 10-Q · filed 2016-11-14 | $10.63M derived: sum of 4 quarters · filed 2016-11-14 | ||
| 2015-06-30 | $2.48M 10-Q · filed 2016-08-15 | $5.11M 10-Q · filed 2016-08-15 | $8.42M derived: sum of 3 quarters · filed 2016-08-15 | $11.02M derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | $2.63M 10-Q · filed 2016-05-13 | $5.94M derived: sum of 2 quarters · filed 2016-05-13 | $8.54M derived: sum of 3 quarters · filed 2016-05-13 | $10.96M derived: sum of 4 quarters · filed 2016-05-13 | ||
| 2014-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $5.92M derived: sum of 2 quarters · filed 2016-03-30 | $8.34M derived: sum of 3 quarters · filed 2016-03-30 | $10.46M 10-K · filed 2016-03-30 | ||
| 2014-09-30 | $2.61M 10-Q · filed 2015-11-10 | $5.03M derived: sum of 2 quarters · filed 2015-11-10 | $7.15M 10-Q · filed 2015-11-10 | $8.96M derived: sum of 4 quarters · filed 2015-11-10 | ||
| 2014-06-30 | $2.42M 10-Q · filed 2015-08-13 | $4.55M 10-Q · filed 2015-08-13 | $6.35M derived: sum of 3 quarters · filed 2015-08-13 | $7.81M derived: sum of 4 quarters · filed 2015-08-13 | ||
| 2014-03-31 | $2.13M 10-Q · filed 2015-05-15 | $2.13M 10-Q · filed 2014-06-06 | $3.93M derived: sum of 2 quarters · filed 2015-05-15 | $5.39M derived: sum of 3 quarters · filed 2015-05-15 | $5.73M derived: sum of 4 quarters · filed 2015-05-15 | $5.96M 10-Q · filed 2014-06-06 |
| 2013-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $3.26M derived: sum of 2 quarters · filed 2015-03-31 | $3.60M derived: sum of 3 quarters · filed 2015-03-31 | $3.71M 10-K · filed 2015-03-31 | ||
| 2013-09-30 | $1.45M 10-Q · filed 2014-11-14 | $1.80M derived: sum of 2 quarters · filed 2014-11-14 | $1.91M 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | $343.37K 10-Q · filed 2014-08-08 | $455.50K 10-Q · filed 2014-08-08 | ||||
| 2013-03-31 | $112.13K 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |